This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving [Yahoo! Finance]
AnaptysBio (NASDAQ:ANAB) had its "buy" rating reaffirmed by analysts at Guggenheim.
AnaptysBio (NASDAQ:ANAB) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at Stifel Nicolaus from $80.00 to $56.00. They now have a "buy" rating on the stock.
SA Quant ranks Goldman's small-cap stocks with largest short interest [Seeking Alpha]